Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer : a population-based study of 1,542 consecutive patients. / Larsen, Christian Grønhøj; Jensen, David H; Carlander, Amanda-Louise Fenger; Kiss, Katalin; Andersen, Luise; Holkmann Olsen, Caroline; Andersen, Elo; Garnæs, Emilie; Cilius, Finn Cilius; Specht, Lena; von Buchwald, Christian.

I: OncoTarget, Bind 7, Nr. 44, 2016, s. 71761-71772.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Larsen, CG, Jensen, DH, Carlander, A-LF, Kiss, K, Andersen, L, Holkmann Olsen, C, Andersen, E, Garnæs, E, Cilius, FC, Specht, L & von Buchwald, C 2016, 'Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients', OncoTarget, bind 7, nr. 44, s. 71761-71772. https://doi.org/10.18632/oncotarget.12335

APA

Larsen, C. G., Jensen, D. H., Carlander, A-L. F., Kiss, K., Andersen, L., Holkmann Olsen, C., ... von Buchwald, C. (2016). Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients. OncoTarget, 7(44), 71761-71772. https://doi.org/10.18632/oncotarget.12335

Vancouver

Larsen CG, Jensen DH, Carlander A-LF, Kiss K, Andersen L, Holkmann Olsen C o.a. Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients. OncoTarget. 2016;7(44):71761-71772. https://doi.org/10.18632/oncotarget.12335

Author

Larsen, Christian Grønhøj ; Jensen, David H ; Carlander, Amanda-Louise Fenger ; Kiss, Katalin ; Andersen, Luise ; Holkmann Olsen, Caroline ; Andersen, Elo ; Garnæs, Emilie ; Cilius, Finn Cilius ; Specht, Lena ; von Buchwald, Christian. / Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer : a population-based study of 1,542 consecutive patients. I: OncoTarget. 2016 ; Bind 7, Nr. 44. s. 71761-71772.

Bibtex

@article{c42eb99758ad46f38169cd7402dc094b,
title = "Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients",
abstract = "BACKGROUND: No study has combined tumour and clinical covariates for survival to construct an individual risk-profile for overall survival (OS), time to progression (TTP), and survival after progression (SAP) in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma (OPSCC). Based on the largest-to-date, unselected, population-based cohort of patients diagnosed with OPSCC, we performed a comprehensive analysis of long-term OS, TTP, and SAP and constructed novel nomograms to evaluate patients' prognoses.RESULTS: At a median follow-up of 4.0 years (range: 0.8-15.8 yrs.), 690 deaths were recorded. The 5-year OS, TTP, and SAP for the HPV+/p16+ subgroup were 77{\%}, 82{\%}, and 33, vs. 30{\%}, 66{\%}, and 6{\%} for the HPV-/p16- group (P < 0.01). 376 patients failed to maintain disease control with a median TTP of 13 months in the HPV+/p16+ subgroup vs. 8.5 months in the HPV-/p16- subgroup (P < 0.05). HPV combined with p16 status remained one of the most informative covariates in the final Cox regression model for OS, TTP, and SAP.METHODS: We included all patients diagnosed with OPSCC (n = 1,542) between 2000-2014 in Eastern Denmark. Survival rates were estimated by the Kaplan-Meier method. A multivariate Cox regression model was used to construct predictive, internally validated nomograms.CONCLUSION: The HPV+/p16+ subgroup had improved OS, TTP, and SAP compared with other combinations of HPV and p16 after adjusting for covariates. Nomograms were constructed for 1-, 5- and 10-year survival probability. Models may aid patients and clinicians in their clinical decision making as well as in counselling, research, and trial design.",
author = "Larsen, {Christian Gr{\o}nh{\o}j} and Jensen, {David H} and Carlander, {Amanda-Louise Fenger} and Katalin Kiss and Luise Andersen and {Holkmann Olsen}, Caroline and Elo Andersen and Emilie Garn{\ae}s and Cilius, {Finn Cilius} and Lena Specht and {von Buchwald}, Christian",
year = "2016",
doi = "10.18632/oncotarget.12335",
language = "English",
volume = "7",
pages = "71761--71772",
journal = "OncoTarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "44",

}

RIS

TY - JOUR

T1 - Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer

T2 - a population-based study of 1,542 consecutive patients

AU - Larsen, Christian Grønhøj

AU - Jensen, David H

AU - Carlander, Amanda-Louise Fenger

AU - Kiss, Katalin

AU - Andersen, Luise

AU - Holkmann Olsen, Caroline

AU - Andersen, Elo

AU - Garnæs, Emilie

AU - Cilius, Finn Cilius

AU - Specht, Lena

AU - von Buchwald, Christian

PY - 2016

Y1 - 2016

N2 - BACKGROUND: No study has combined tumour and clinical covariates for survival to construct an individual risk-profile for overall survival (OS), time to progression (TTP), and survival after progression (SAP) in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma (OPSCC). Based on the largest-to-date, unselected, population-based cohort of patients diagnosed with OPSCC, we performed a comprehensive analysis of long-term OS, TTP, and SAP and constructed novel nomograms to evaluate patients' prognoses.RESULTS: At a median follow-up of 4.0 years (range: 0.8-15.8 yrs.), 690 deaths were recorded. The 5-year OS, TTP, and SAP for the HPV+/p16+ subgroup were 77%, 82%, and 33, vs. 30%, 66%, and 6% for the HPV-/p16- group (P < 0.01). 376 patients failed to maintain disease control with a median TTP of 13 months in the HPV+/p16+ subgroup vs. 8.5 months in the HPV-/p16- subgroup (P < 0.05). HPV combined with p16 status remained one of the most informative covariates in the final Cox regression model for OS, TTP, and SAP.METHODS: We included all patients diagnosed with OPSCC (n = 1,542) between 2000-2014 in Eastern Denmark. Survival rates were estimated by the Kaplan-Meier method. A multivariate Cox regression model was used to construct predictive, internally validated nomograms.CONCLUSION: The HPV+/p16+ subgroup had improved OS, TTP, and SAP compared with other combinations of HPV and p16 after adjusting for covariates. Nomograms were constructed for 1-, 5- and 10-year survival probability. Models may aid patients and clinicians in their clinical decision making as well as in counselling, research, and trial design.

AB - BACKGROUND: No study has combined tumour and clinical covariates for survival to construct an individual risk-profile for overall survival (OS), time to progression (TTP), and survival after progression (SAP) in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma (OPSCC). Based on the largest-to-date, unselected, population-based cohort of patients diagnosed with OPSCC, we performed a comprehensive analysis of long-term OS, TTP, and SAP and constructed novel nomograms to evaluate patients' prognoses.RESULTS: At a median follow-up of 4.0 years (range: 0.8-15.8 yrs.), 690 deaths were recorded. The 5-year OS, TTP, and SAP for the HPV+/p16+ subgroup were 77%, 82%, and 33, vs. 30%, 66%, and 6% for the HPV-/p16- group (P < 0.01). 376 patients failed to maintain disease control with a median TTP of 13 months in the HPV+/p16+ subgroup vs. 8.5 months in the HPV-/p16- subgroup (P < 0.05). HPV combined with p16 status remained one of the most informative covariates in the final Cox regression model for OS, TTP, and SAP.METHODS: We included all patients diagnosed with OPSCC (n = 1,542) between 2000-2014 in Eastern Denmark. Survival rates were estimated by the Kaplan-Meier method. A multivariate Cox regression model was used to construct predictive, internally validated nomograms.CONCLUSION: The HPV+/p16+ subgroup had improved OS, TTP, and SAP compared with other combinations of HPV and p16 after adjusting for covariates. Nomograms were constructed for 1-, 5- and 10-year survival probability. Models may aid patients and clinicians in their clinical decision making as well as in counselling, research, and trial design.

U2 - 10.18632/oncotarget.12335

DO - 10.18632/oncotarget.12335

M3 - Journal article

VL - 7

SP - 71761

EP - 71772

JO - OncoTarget

JF - OncoTarget

SN - 1949-2553

IS - 44

ER -

ID: 177391154